KPTI Selinexor Fails Phase 3 Endometrial Cancer Trial

Karyopharm Therapeutics (KPTI) reported on July 30 that its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer failed to meet its primary endpoint of progression-free survival.

The trial randomized 257 patients (mITT population n=236) to selinexor or placebo as maintenance following chemotherapy or chemo plus a checkpoint inhibitor. Median PFS was 12.75 months in the selinexor arm versus 7.43 months for placebo, a 5.3-month numerical advantage. The hazard ratio was 0.76, but the 95% confidence interval of 0.51 to 1.12 crossed 1.0, and the one-sided p-value of 0.0791 fell short of significance. Only 106 PFS events had been observed at data cutoff, which likely contributed to the wide interval. The drug showed biological activity, but the trial was underpowered to prove it.

Karyopharm trades at $1.92 with a market cap near $159 million, making it a microcap whose value depends on expanding selinexor beyond its two approved indications: multiple myeloma (in combination with bortezomib and dexamethasone) and diffuse large B-cell lymphoma (as a single agent). Selinexor works by inhibiting XPO1, a nuclear export protein that shuttles tumor suppressor proteins out of the cell nucleus. Blocking XPO1 traps those proteins inside the nucleus, restoring their ability to suppress tumor growth. The endometrial cancer program was a push into solid tumors, a harder setting for a drug with established hematologic activity.

The failure narrows Karyopharm’s near-term pipeline to a single catalyst: an sNDA filing planned for August 2026 seeking accelerated approval of selinexor plus ruxolitinib in myelofibrosis. That filing is based on the Phase 3 SENTRY trial (N=353), which met its first co-primary endpoint of SVR35 (spleen volume reduction of at least 35% at week 24) with a near-doubling of response rates versus placebo plus ruxolitinib. The FDA agreed in writing that SVR35 qualifies as a reasonably likely surrogate endpoint for accelerated approval. The trial also showed a promising overall survival signal and reductions in variant allele frequency, hinting at disease modification.

Myelofibrosis is currently treated exclusively with JAK inhibitors: ruxolitinib (Incyte’s Jakafi), fedratinib, pacritinib, and momelotinib. If approved, selinexor plus ruxolitinib would be the first combination therapy incorporating a novel drug class. Karyopharm will request Priority Review, which if granted would put a PDUFA date roughly six months after FDA receipt, placing a decision in early-to-mid 2027. The company plans to submit the sNDA in August.

The endometrial cancer readout shows the risk of extending XPO1 inhibition into solid tumors, where the biology may be less favorable than in hematologic malignancies. Analysts had already cut Karyopharm price targets aggressively, with HC Wainwright reducing from $13 to $3 and Piper Sandler from $16 to $7, reflecting diminished expectations ahead of the XPORT-EC-042 readout.

What to watch next: the August sNDA submission for selinexor plus ruxolitinib in myelofibrosis and whether the FDA grants Priority Review. That decision determines whether Karyopharm gets a 6-month or 10-month review window, and it is now the company’s only near-term value driver.

Source: Karyopharm XPORT-EC-042 topline results press release | XPORT-EC-042 on ClinicalTrials.gov (NCT05611931)

What It Means for the Trade

Read the numbers the way the FDA will: a 5.3-month median PFS advantage with a hazard ratio of 0.76 is biological activity, but a confidence interval crossing 1.0 with p=0.0791 is a failed trial, and the 106-event cutoff explains why — the study was sized for more events than it got. That is the most frustrating failure mode in oncology: not a drug that did nothing, but a trial that could not prove what the drug plausibly did. For a $159 million microcap, the difference matters enormously, because selinexor’s approved myeloma and DLBCL labels keep the lights on while the myelofibrosis sNDA — now the entire growth story — runs.

The trade is now a single-file bet on the August sNDA and its Priority Review decision. The SENTRY trial’s near-doubling of SVR35 responses, a pre-agreed accelerated-approval endpoint, plus an overall-survival hint and VAF reductions, is a strong filing package. A Priority grant puts a PDUFA in early-to-mid 2027; a standard review pushes it late 2027 and stretches a microcap’s cash further than the market will comfortably discount.

The analyst repositioning (HCW $13-to-$3, Piper $16-to-$7) already happened ahead of the readout, so the endometrial miss was priced. What was not priced is myelofibrosis optionality at current levels — that is the asymmetry.

Mechanism and Market Context

XPO1 inhibition is a mechanism with proven but narrow reach: forcing tumor-suppressor retention in the nucleus works in certain hematologic settings (selinexor’s myeloma and DLBCL labels), and the endometrial maintenance attempt was the solid-tumor stretch. The XPORT-EC-042 signal — 12.75 versus 7.43 months median PFS in a maintenance population — suggests the biology transfers imperfectly: enough activity to see, not enough to prove. TP53 wild-type selection was rational (p53-intact tumors should be more vulnerable to nuclear-retained suppressors), yet even enrichment did not rescue statistical power.

The myelofibrosis setup is scientifically cleaner. Myelofibrosis is an inflammatory myeloproliferative neoplasm where XPO1-mediated nuclear export contributes to malignant clone fitness, and the combination logic — selinexor attacking the clone alongside ruxolitinib taming the cytokine syndrome — is the first novel-class add-on to JAK inhibition in a field that has been JAK-only for over a decade. SENTRY’s SVR35 near-doubling with VAF declines is exactly the disease-modification signal myelofibrosis investors hunt for, and the pre-agreed surrogate endpoint means the regulatory bar is defined rather than discretionary.

Risks and What Could Go Wrong

1. Priority Review denied. A standard 10-month clock extends the cash runway question past the market’s patience for a $159 million microcap.
2. CRL or delay on the sNDA. Manufacturing or data-package issues at filing would leave the company with no near-term catalyst and a financing overhang.
3. Solid-tumor writedown effects. Further XPO1 solid-tumor attempts now carry the endometrial precedent; the platform’s total addressable story shrinks.
4. Accelerated-approval confirmation risk. Even on approval, selinexor-ruxolitinib would carry confirmatory obligations, and this company just learned what failed confirmatory trials do to a franchise.

Net: one clean miss, one concentrated bet left. The myelofibrosis filing decision is the whole trade — position sizing should reflect binary review risk at microcap scale.